Cost effectiveness of continued-Warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery

Doug Coyle; Kathryn Coyle; Vidal Essebag; David H. Birnie; Kamran Ahmad; Satish Toal; John Sapp; Jeffrey S. Healey; Atul Verma; George Wells; Andrew D. Krahn

doi:10.1016/j.jacc.2014.11.060

Cost effectiveness of continued-Warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery

Doug Coyle, Kathryn Coyle, Vidal Essebag, David H. Birnie, Kamran Ahmad, Satish Toal, John Sapp, Jeffrey S. Healey, Atul Verma, George Wells, Andrew D. Krahn

Résultat de recherche: Letter › examen par les pairs

13 Citations (Scopus)

Langue d'origine	English
Pages (de-à)	957-959
Nombre de pages	3
Journal	Journal of the American College of Cardiology
Volume	65
Numéro de publication	9
DOI	https://doi.org/10.1016/j.jacc.2014.11.060
Statut de publication	Published - mars 10 2015
Publié à l'externe	Oui

Note bibliographique

Funding Information:
Please note: The BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial) was supported by the Canadian Institutes of Health Research and the Ministry of Health and Long-Term Care of Ontario . The economic analysis was supported by the Canadian Institutes of Health Research . Dr. Essebag has been supported by a Clinician Scientist award from the Canadian Institutes of Health Research . Dr. Sapp has received research funding from Biosense Webster, Philips, and St. Jude Medical; and has served as a consultant for Biosense Webster. Drs. Healey and Birnie have received personnel Mid-Career Investigator awards from the Heart and Stroke Foundation of Ontario (MC7450 and MC7445). Dr. Verma has served as a consultant for Bayer and Boehringer Ingelheim. Dr. Krahn is supported by the Sauder Family and Heart and Stroke Foundation Chair in Cardiology and the Paul Brunes Chair in Heart Rhythm Disorders . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

ASJC Scopus Subject Areas

Cardiology and Cardiovascular Medicine

PubMed: MeSH publication types

Letter
Research Support, Non-U.S. Gov't

Accès au document

10.1016/j.jacc.2014.11.060

Autres fichiers et liens

Citer

@article{31dbae1c10de4132aa70c77de58f5b51,

title = "Cost effectiveness of continued-Warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery",

author = "Doug Coyle and Kathryn Coyle and Vidal Essebag and Birnie, {David H.} and Kamran Ahmad and Satish Toal and John Sapp and Healey, {Jeffrey S.} and Atul Verma and George Wells and Krahn, {Andrew D.}",

note = "Funding Information: Please note: The BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial) was supported by the Canadian Institutes of Health Research and the Ministry of Health and Long-Term Care of Ontario . The economic analysis was supported by the Canadian Institutes of Health Research . Dr. Essebag has been supported by a Clinician Scientist award from the Canadian Institutes of Health Research . Dr. Sapp has received research funding from Biosense Webster, Philips, and St. Jude Medical; and has served as a consultant for Biosense Webster. Drs. Healey and Birnie have received personnel Mid-Career Investigator awards from the Heart and Stroke Foundation of Ontario (MC7450 and MC7445). Dr. Verma has served as a consultant for Bayer and Boehringer Ingelheim. Dr. Krahn is supported by the Sauder Family and Heart and Stroke Foundation Chair in Cardiology and the Paul Brunes Chair in Heart Rhythm Disorders . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. ",

year = "2015",

month = mar,

day = "10",

doi = "10.1016/j.jacc.2014.11.060",

language = "English",

volume = "65",

pages = "957--959",

journal = "Journal of the American College of Cardiology",

issn = "0735-1097",

publisher = "Elsevier USA",

number = "9",

}

TY - JOUR

T1 - Cost effectiveness of continued-Warfarin versus heparin-bridging therapy during pacemaker and defibrillator surgery

AU - Coyle, Doug

AU - Coyle, Kathryn

AU - Essebag, Vidal

AU - Birnie, David H.

AU - Ahmad, Kamran

AU - Toal, Satish

AU - Sapp, John

AU - Healey, Jeffrey S.

AU - Verma, Atul

AU - Wells, George

AU - Krahn, Andrew D.

N1 - Funding Information: Please note: The BRUISE CONTROL (Bridge or Continue Coumadin for Device Surgery Randomized Controlled Trial) was supported by the Canadian Institutes of Health Research and the Ministry of Health and Long-Term Care of Ontario . The economic analysis was supported by the Canadian Institutes of Health Research . Dr. Essebag has been supported by a Clinician Scientist award from the Canadian Institutes of Health Research . Dr. Sapp has received research funding from Biosense Webster, Philips, and St. Jude Medical; and has served as a consultant for Biosense Webster. Drs. Healey and Birnie have received personnel Mid-Career Investigator awards from the Heart and Stroke Foundation of Ontario (MC7450 and MC7445). Dr. Verma has served as a consultant for Bayer and Boehringer Ingelheim. Dr. Krahn is supported by the Sauder Family and Heart and Stroke Foundation Chair in Cardiology and the Paul Brunes Chair in Heart Rhythm Disorders . All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

PY - 2015/3/10

Y1 - 2015/3/10

UR - http://www.scopus.com/inward/record.url?scp=84924666790&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924666790&partnerID=8YFLogxK

U2 - 10.1016/j.jacc.2014.11.060

DO - 10.1016/j.jacc.2014.11.060

M3 - Letter

C2 - 25744016

AN - SCOPUS:84924666790

SN - 0735-1097

VL - 65

SP - 957

EP - 959

JO - Journal of the American College of Cardiology

JF - Journal of the American College of Cardiology

IS - 9

ER -